SBC Medical Group Holdings Inc. (NASDAQ: SBC), a Japanese owner and operator of aesthetic medical clinics, has laid a strong foundation for growth in 2026 following a year marked by significant expansion, strategic acquisitions, and market entries. The company's initiatives in 2025 focused on making aesthetic medicine more accessible and differentiating its offerings through advanced treatments and competitive pricing, resulting in increased clinic numbers, customer loyalty, and revenue.
As of September 30, 2025, SBC Medical's franchise locations reached 258, a 15% year-over-year increase. The company's revised pricing strategy led to a 5% sequential rise in average revenue per customer in the third quarter, driven by pricing optimization and a multi-brand approach that attracted higher-revenue clients. New services, including plastic surgery and infertility treatments, are expected to strengthen its market share in specialized medical care.
Internationally, SBC Medical expanded to Singapore and Thailand, and in early 2026, announced its first U.S. expansion. In Thailand, the company signed an e-consulting agreement with BLEZ ASIA Co. Ltd., a network of pharmacies and clinics, to provide management support for a new dermatology-focused clinic in Bangkok. In Singapore, SBC is expanding its collaboration with Aesthetic Healthcare Holdings Pte. Ltd., acquired in 2024.
Domestically, the company launched two new brands: "Neo Skin Clinic" and "Hada no Aozora Clinic" in Tokyo. The latter uses a hybrid dermatology model combining insurance-covered general dermatology with private-pay aesthetic treatments. SBC also acquired MB Career Lounge Co. Ltd., a provider of management support services for medical institutions, and Waqoo, a related subsidiary, to accelerate R&D and integrate technologies for clinical areas such as AGA and orthopedics.
Financially, SBC Medical reported a significant improvement in net profit for the third quarter of 2025, returning to a more typical cost structure after IPO-related expenses. Average revenue per visit rose 5% sequentially to $298, and the repeat customer rate stood at 72%. The company ended the quarter with 258 locations, up 15% year-over-year.
SBC Medical's growth trajectory caught Wall Street's attention, earning it a spot on the Russell 3000® Index, which automatically includes it in the large-cap Russell 1000 or small-cap Russell 2000 indexes. This inclusion increases visibility among institutional and individual investors who track the indexes, with about $18.1 trillion in assets benchmarked against them globally. The company also announced a stock buyback program of up to $5 million, reflecting confidence in its growth plan and belief that its stock was undervalued.
To capitalize on cosmetic tourism, SBC is targeting Chinese consumers visiting Japan for procedures, adding Chinese-speaking staff, disseminating information on Chinese social media, and developing a dedicated app. The global cosmetic surgery market, valued at $122.08 billion in 2022, is expected to grow at a CAGR of 14.7% through 2030, positioning SBC Medical to benefit from rising demand.
With $125 million in cash at the start of 2025, the company made strategic acquisitions and market entries that set the stage for 2026. As the aesthetic medicine market heats up, SBC Medical is ready to capitalize on the growing demand from domestic and international clients.
